platelet aggregation inhibitors

Preferred Label : platelet aggregation inhibitors;

MeSH definition : Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.;

MeSH synonym : platelet antiaggregants; antiaggregants, platelet; blood platelet aggregation inhibitors; blood platelet antiaggregants; Platelet Antiaggregant; Antiaggregant, Platelet; Blood Platelet Aggregation Inhibitor; Blood Platelet Antiaggregant; Antiaggregant, Blood Platelet; Platelet Antiaggregant, Blood; Platelet Aggregation Inhibitor; Aggregation Inhibitor, Platelet; Inhibitor, Platelet Aggregation;

CISMeF synonym : antiaggregants, blood platelet; aggregation inhibitors, platelet; inhibitors, platelet aggregation;

MeSH Hyperonym : platelet antagonists; antiplatelet agents; platelet inhibitors; Inhibitors, Platelet; Agents, Antiplatelet; Antiplatelet Drugs; Drugs, Antiplatelet; Antagonists, Platelet; Blood Platelet Antagonists; Antagonists, Blood Platelet; Platelet Inhibitor; Inhibitor, Platelet; Antiplatelet Agent; Agent, Antiplatelet; Antiplatelet Drug; Drug, Antiplatelet; Blood Platelet Antagonist; Antagonist, Blood Platelet; Platelet Antagonist, Blood; Platelet Antagonist; Antagonist, Platelet;

MeSH hyponym : Protease Activated Receptor 1 Antagonists; PAR-1 Antagonists; PAR 1 Antagonists;

MeSH annotation : DF: PLATELET INHIB;

Wikipedia link : https://en.wikipedia.org/wiki/Antiplatelet drug;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D010975;

UMLS CUI

C0032177;

ATC code(s)
- acetylsalicylic acid [ATC Code]
- acetylsalicylic acid, combinations with proton pump inhibitors [ATC Code]
- aloxiprin [ATC Code]
- carbasalate calcium [ATC Code]
- cilostazol [ATC Code]
- iloprost [ATC Code]
- platelet aggregation inhibitors excl. heparin [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA [NCIt concept]
- Acute apical periodontitis of pulpal origin [ICD-11 Sub-sub category]
- Acute promyelocytic leukaemia with t(15;17)(q24.1;q21.1), PML-RARA [ICD-11 More detail]
- Acute promyelocytic leukemia [OMIM Phenotype]
- Alanine Aminopeptidase Measurement [NCIt concept]
- Aminopeptidase N [NCIt concept]
- Aneurysm of pulmonary artery [ICD-11 Subcategory]
- Antiplatelet Agent [NCIt concept]
- Antiplatelet agent (substance) [SNOMED CT concept]
- Atrichia with papular lesions [OMIM Phenotype]
- Medicinal product acting as antiplatelet agent (product) [Inactive SNOMED CT concept]
- Pancreatic acinar atrophy (disorder) [SNOMED CT concept]
- Platelet aggregation inhibitor [LOINC component]
- Platelet aggregation inhibitor (disposition) [SNOMED CT concept]
- SERPINF2 wt Allele [NCIt concept]
- Substance with platelet aggregation inhibitor mechanism of action (substance) [SNOMED CT concept]
- antiplatelet agent [Blood Transfusion thesaurus concept]
- blood thinners [MedlinePlus Topic]
CISMeF manual mappings
- Platelet aggregation inhibitors [Bloc CIM-11]
False automatic mappings
- Atypical antipsychotic (substance) [Inactive SNOMED CT concept]
Indexing information
- 2-(benzyl(2-((4-carbamimidoylphenoxy)methyl)-2,3-dihydro-1,4-benzodioxin-6-yl)amino)-2-oxoacetic acid [MeSH Supplementary Concept]
- 2-methylthio-6-phenethylaminoadenosine [MeSH Supplementary Concept]
- 2-morpholino-5-(thienyl-2)-6-H-1,3,4-thiadiazine [MeSH Supplementary Concept]
- KT-6.9 peptide, Naja kaouthia [MeSH Supplementary Concept]
- MWReg30 monoclonal antibody [MeSH Supplementary Concept]
- N(9)-imidazo-(1,2)-benzimidazol [MeSH Supplementary Concept]
- OPC 29030 [MeSH Supplementary Concept]
- P2ry12 protein, rat [MeSH Supplementary Concept]
- SDZ GPI 562 [MeSH Supplementary Concept]
- SR 121566 [MeSH Supplementary Concept]
- Troglitazone [MeSH Descriptor]
- aegyptin protein, aedes aegypti [MeSH Supplementary Concept]
- azelastine [MeSH Supplementary Concept]
- batifiban [MeSH Supplementary Concept]
- buflomedil [MeSH Supplementary Concept]
- epinastine [MeSH Supplementary Concept]
- ifenprodil [MeSH Supplementary Concept]
- jerdostatin, protobothrops jerdonii [MeSH Supplementary Concept]
- magnoline [MeSH Supplementary Concept]
- methyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate [MeSH Supplementary Concept]
- methyl 6-nitroarachidonate [MeSH Supplementary Concept]
- nimesulide [MeSH Supplementary Concept]
- qushuanling [MeSH Supplementary Concept]
- rhombeobin protein, Lachesis muta rhombeata [MeSH Supplementary Concept]
- rutecarpine [MeSH Supplementary Concept]
- tetramethylpyrazine [MeSH Supplementary Concept]
MedlinePlus topic(s)
- blood thinners [MedlinePlus Topic]
Metaterm(s)
- cardiology [CISMeF Metaterm]
Record concept(s)
- Protease-Activated Receptor-1 Antagonists [MeSH concept]
- antiplatelet agents [MeSH concept]
- platelet aggregation inhibitors [MeSH concept]
- platelet antagonists [MeSH concept]
- platelet inhibitors [MeSH concept]
See also
- Dual Anti-Platelet Therapy [MeSH Descriptor]
- blood platelets [MeSH Descriptor]
See also (suggested by CISMeF)
- platelet aggregation [MeSH Descriptor]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- (2S)-2-(4-(((3S)-1-acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphtyl)propanoic acid [MeSH Supplementary Concept]
- 1,2-benzisothiazoline-3-one [MeSH Supplementary Concept]
- 1,2-dipalmitoyl-3-phosphatidylethanolamine [MeSH Supplementary Concept]
- 1,5-dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3H)-one [MeSH Supplementary Concept]
- 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole [MeSH Supplementary Concept]
- 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione [MeSH Supplementary Concept]
- 12-HPETE [MeSH Supplementary Concept]
- 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate [MeSH Supplementary Concept]
- 3,4-dihydroxyacetophenone [MeSH Supplementary Concept]
- 3,4-dihydroxyphenylethanol [MeSH Supplementary Concept]
- 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole [MeSH Supplementary Concept]
- 3-n-butylphthalide [MeSH Supplementary Concept]
- 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone [MeSH Supplementary Concept]
- 6-methyl-2-ethyl-3-hydroxypyridine [MeSH Supplementary Concept]
- 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP [MeSH Supplementary Concept]
- 9-O-methanoprostaglandin I [MeSH Supplementary Concept]
- Abciximab [MeSH Descriptor]
- Aspirin, Dipyridamole Drug Combination [MeSH Descriptor]
- BMS-986120 [MeSH Supplementary Concept]
- BN 50730 [MeSH Supplementary Concept]
- BW A868C [MeSH Supplementary Concept]
- CV 3988 [MeSH Supplementary Concept]
- Cilostazol [MeSH Descriptor]
- Clopidogrel [MeSH Descriptor]
- DMP 728 [MeSH Supplementary Concept]
- E 4021 [MeSH Supplementary Concept]
- Eptifibatide [MeSH Descriptor]
- FK 409 [MeSH Supplementary Concept]
- GEA 3162 [MeSH Supplementary Concept]
- IH 764-3 [MeSH Supplementary Concept]
- JLX001 [MeSH Supplementary Concept]
- KW 3635 [MeSH Supplementary Concept]
- MP407 [MeSH Supplementary Concept]
- N-acetylsphingosine [MeSH Supplementary Concept]
- ONO 3708 [MeSH Supplementary Concept]
- Prasugrel Hydrochloride [MeSH Descriptor]
- Quin2 [MeSH Supplementary Concept]
- RS 5186 [MeSH Supplementary Concept]
- Resveratrol [MeSH Descriptor]
- S 145 [MeSH Supplementary Concept]
- S-nitrosocysteine [MeSH Supplementary Concept]
- S-nitrosoglutathione [MeSH Descriptor]
- S-nitrosomercaptoethanol [MeSH Supplementary Concept]
- S-nitrosothiols [MeSH Descriptor]
- S007-867 [MeSH Supplementary Concept]
- SR 46349B [MeSH Supplementary Concept]
- ST 638 [MeSH Supplementary Concept]
- Satigrel [MeSH Supplementary Concept]
- Sevoflurane [MeSH Descriptor]
- TCV 309 [MeSH Supplementary Concept]
- Ticagrelor [MeSH Descriptor]
- Tirofiban [MeSH Descriptor]
- UD CG 212 cl [MeSH Supplementary Concept]
- WEB 2086 [MeSH Supplementary Concept]
- acetylphenylalanyl-prolyl-boroarginine [MeSH Supplementary Concept]
- acetylsalicylic acid lysinate [MeSH Supplementary Concept]
- ajoene [MeSH Supplementary Concept]
- aloxistatin [MeSH Supplementary Concept]
- alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol [MeSH Supplementary Concept]
- alprostadil [MeSH Descriptor]
- anagrelide [MeSH Supplementary Concept]
- andrographolide [MeSH Supplementary Concept]
- argatroban [MeSH Supplementary Concept]
- arginyl-glycyl-aspartyl-serine [MeSH Supplementary Concept]
- aspirin [MeSH Descriptor]
- ataprost [MeSH Supplementary Concept]
- atrinositol [MeSH Supplementary Concept]
- bepafant [MeSH Supplementary Concept]
- beraprost [MeSH Supplementary Concept]
- canadine [MeSH Supplementary Concept]
- cangrelor [MeSH Supplementary Concept]
- carboprostacyclin [MeSH Supplementary Concept]
- cilostamide [MeSH Supplementary Concept]
- clentiazem [MeSH Supplementary Concept]
- clopidogrel carboxylic acid [MeSH Supplementary Concept]
- cloricromen [MeSH Supplementary Concept]
- daltroban [MeSH Supplementary Concept]
- dauricine [MeSH Supplementary Concept]
- dazmegrel [MeSH Supplementary Concept]
- defibrotide [MeSH Supplementary Concept]
- diadenosine tetraphosphate [MeSH Supplementary Concept]
- diallyl trisulfide [MeSH Supplementary Concept]
- dipyridamole [MeSH Descriptor]
- disintegrins [MeSH Descriptor]
- draflazine [MeSH Supplementary Concept]
- echistatin [MeSH Supplementary Concept]
- efegatran [MeSH Supplementary Concept]
- eicosapentaenoic acid ethyl ester [MeSH Supplementary Concept]
- emoxypine succinate [MeSH Supplementary Concept]
- enfenamic acid [MeSH Supplementary Concept]
- epoprostenol [MeSH Descriptor]
- essential 303 forte [MeSH Supplementary Concept]
- fibrinopeptides gamma [MeSH Supplementary Concept]
- foropafant [MeSH Supplementary Concept]
- glycocalicin [MeSH Supplementary Concept]
- glycyl-arginyl-glycyl-aspartyl-serine [MeSH Supplementary Concept]
- helenalin [MeSH Supplementary Concept]
- ibudilast [MeSH Supplementary Concept]
- ifetroban [MeSH Supplementary Concept]
- iloprost [MeSH Descriptor]
- indobufen [MeSH Supplementary Concept]
- jararhagin [MeSH Supplementary Concept]
- ketanserin [MeSH Descriptor]
- lamifiban [MeSH Supplementary Concept]
- linsidomine [MeSH Supplementary Concept]
- magnolol [MeSH Supplementary Concept]
- milrinone [MeSH Descriptor]
- naftopidil [MeSH Supplementary Concept]
- nitroaspirin [MeSH Supplementary Concept]
- oxophenylarsine [MeSH Supplementary Concept]
- pentoxifylline [MeSH Descriptor]
- picotamide [MeSH Supplementary Concept]
- piroximone [MeSH Supplementary Concept]
- plafibride [MeSH Supplementary Concept]
- policosanol [MeSH Supplementary Concept]
- protopine [MeSH Supplementary Concept]
- pycnogenols [MeSH Supplementary Concept]
- pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid [MeSH Supplementary Concept]
- ramatroban [MeSH Supplementary Concept]
- relcovaptan [MeSH Supplementary Concept]
- rhodostomin [MeSH Supplementary Concept]
- ridogrel [MeSH Supplementary Concept]
- ro 31-7549 [MeSH Supplementary Concept]
- ro 31-8220 [MeSH Supplementary Concept]
- rosmarinic acid [MeSH Supplementary Concept]
- sarpogrelate [MeSH Supplementary Concept]
- sibrafiban [MeSH Supplementary Concept]
- sulotroban [MeSH Supplementary Concept]
- tautomycin [MeSH Supplementary Concept]
- tesmilifene [MeSH Supplementary Concept]
- thromboxane A2, carbocyclic [MeSH Supplementary Concept]
- ticlopidine [MeSH Descriptor]
- tranilast [MeSH Supplementary Concept]
- trapidil [MeSH Descriptor]
- trequinsin [MeSH Supplementary Concept]
- triflavin [MeSH Supplementary Concept]
- triflusal [MeSH Supplementary Concept]
- trilinolein [MeSH Supplementary Concept]
- vapiprost [MeSH Supplementary Concept]
- vorapaxar [MeSH Supplementary Concept]
- xemilofiban [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Platelet aggregation inhibitor [LOINC component]
- Platelet aggregation inhibitors [Bloc CIM-11]
- Product containing platelet aggregation inhibitor (product) [SNOMED CT concept]
- Substance with platelet aggregation inhibitor mechanism of action (substance) [SNOMED CT concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients